What do systematic reviews say?

Adalimumab every other week vs placebo

Adalimumab every other week showed no clear difference in frequency of treatment discontinuation compared with placebo (high certainty).

• Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
  RR 4.91 [0.24, 99.74]
  2 studies · 124 participants
  High

Adalimumab every other week vs placebo

Adalimumab every other week showed no clear difference in proportion of participants with infectious adverse effects compared with placebo (high certainty).

• Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
  RR 1.6 [0.57, 4.53]
  2 studies · 124 participants
  High

Adalimumab every other week vs placebo

• Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 21 participants
  Low

Adalimumab every other week vs placebo

Adalimumab every other week showed no clear difference in proportion with improvement in pain compared with placebo (moderate certainty).

• Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
  RR 1.34 [0.73, 2.43]
  1 study · 95 participants
  Moderate

Adalimumab every other week vs placebo

• Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 124 participants
  Moderate

Adalimumab every other week vs placebo

• Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 124 participants
  High

Adalimumab every other week vs placebo

Adalimumab every other week showed no clear difference in frequency of serious adverse effects compared with placebo (high certainty).

• Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
  RR 1.47 [0.26, 8.44]
  2 studies · 124 participants
  High